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Identity 
Hugo: MME 
Other names: common acute lymphocytic leukemia 
antigen (CALLA); CD10; DKFZp686O16152; 
MGC126681; MGC126707; Kidney-brush-border 
neutral proteinase; Neprilysin (NEP); Enkephalinase; 
Atriopeptidase; Endopeptidase-2;Neutral endopeptidase 
Location: 3q25.2 
Note: Membrane metallo-endopeptidase (MME) is a 
100-kD type II transmembrane glycoprotein originally 
described on human acute lymphoblastic leukemia cell 
lines and therefore it was originally designated as 
common acute lymphocytic leukemia antigen 
(CALLA). MME is a neutral endopeptidase that 
cleaves peptides at the amino side of hydrophobic 
residues and inactivates several peptide hormones 
including atrial natriuretic factor, glucagon, enkephalin, 
substance P, neurotensin, oxytocin, and bradykinin. It 
is also a major enzyme for degradation of beta-
amyloid. 
DNA/RNA 
Note: Gene: on chromosome 3 at location: 156284651-
156384186; length: 99536; type: protein coding. 
Description 
MME gene spans a region of 99536 bases and has 24 
exons. Exons 1 and 2 encode 5' untranslated sequences. 
Initiation codon and transmembrane and cytoplasmic 
domain are encoded by exon 3, which has 170 bp. 20 
short exons (exons 4-23) range in size from 36 to 162 
bp. They encode large part of the extracellular portion 
of the enzyme. Exon 24 which has about 3400 bp 
encodes the COOH-terminal 32 amino acids and 
contains the entire 3' untranslated region (UTR). Exon 
19 encodes the pentapeptide sequence associated with 
metalloproteinase zinc binding and substrate catalysis 
(His-Glu-Ile-Thr-His). 
The sequence is nearly identical to rat and rabbit NEP. 
Transcriptional regulation: MME is constitutively 
expressed in some tissues (kidney, adipose tissue, 
brain) and at some developmental stages in other (T- 
and B-lymphocytes, neutrophils). Its gene transcription 
is regulated by at least two alternative regulation 
regions including type 1 and type 2 promoter. Both 
regulatory regions are characterized by the presence of 
multiple transcription initiation sites and the absence of 
classic TATA boxes and consensus initiator elements. 
The purine-rich type 1 regulatory region, which 
includes 5' UTR exon 1 sequence, is characterized by 
multiple putative PU. l-binding sites and consensus ets-
binding motifs. In marked contrast, the GC-rich type 2 
regulatory region contains multiple putative Sp-l-
binding sites, a potential consensus retinoblastoma 
control element (RCE); and an inverted CCAAT box. 
Type 2 promoter has a wide tissue distribution, a low 
constitutive level of expression, and multiple 
transcription initiation sites. However, normal and 
malignant lymphoid progenitors (fetal thymocytes and 
pre-B ALL) as well as fetal kidney and glioblastoma 
cell line A172 showed significantly higher levels of 
type 1 transcripts. 
Transcription 
The 5' untranslated region of this gene is alternatively 
spliced, resulting in four separate mRNA transcripts. 
The coding region is not affected by alternative 
splicing. The transcript variants 1, 1bis, and 2a contain 
an alternate 5' UTR exon, compared to variant 2b. The 
2b variant is the longest transcript and includes 
alternate exon 2b. Variants 2b, 2a, 1bis and 1 all 
encode the same protein. 
Transcript variant 1 mRNA has 5643 bp. Transcript 
variant 1bis mRNA has 5619 bp. Transcript variant 2a 
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mRNA has 5665 bp. Transcript variant 2b mRNA has 
5710 bp. 
In normal human tissues, the highest mRNA levels 
were found in kidney, prostate, liver, and lung. Other 
tissues with high levels include whole blood, bone 
marrow, thymus, skeletal muscle, brain, ovary, testis, 
and placenta. Levels in lymph nodes and other 
secondary lymphoid tissues are dependent on the 
content of CD10+ B-cells in secondary germinal 
centers. 
Protein 
Note: MME belongs to peptidase family M13, which 
belongs to a peptidase superfamily known as the 
metzincins. These are zinc-dependent 
metallopeptidases. Family M13 also includes 
endothelin-converting enzyme 1 (ECE-1), Kell blood 
group glycoprotein, and peptidase O from Lactococcus 
lactis (gene pepO). 
Description 
MME protein contains 750 amino acids, and is a type-II 
membrane anchored enzyme known to inactivate 
oligopeptides. It has a single 24-amino acid 
hydrophobic segment that could function as both a 
transmembrane region and a signal peptide. The 
COOH-terminal 700 amino acids compose the 
extracellular protein segment, whereas the 25 NH2-
terminal amino acids remaining after cleavage of the 
initiation methionine form the cytoplasmic tail. 
Function 
Thermolysin-like specificity, but is almost confined on 
acting on polypeptides of up to 30 amino acids. 
Biologically important in the destruction of opioid 
peptides by cleavage of a Gly-Phe bond. Involved in 
the degradation of atrial natriuretic factor. 
Preferential cleavage of polypeptides between 
hydrophobic residues, particularly with Phe or Tyr at 
P1'. Inhibited in a dose dependent manner by 
opiorphin. Inhibited by phosphoramidon and thiorphan. 
Mutations 
Note: Truncating mutations in the MME gene in 
mothers are the cause of alloimmunisation during 
pregnancy (1342 C to T nonsense mutation and 
446delC). The absence of the MMP protein in pregnant 
women induces an alloimmunisation against MMP 
presented by fetus. Maternal antibodies attack fetal 
podocytes ensuing nephron loss, which could lead to 
chronic renal failure in early adulthood. This is the first 
model of idiopathic renal failure in early adulthood, 
which appears to be caused by immune-mediated fetal 
nephron loss. 
 
 
Implicated in 
Alzheimer disease and normal aging 
Note: Decreased MME expression in cerebral cortex 
correlates with amyloid-beta deposition but not with 
degeneration and dementia. 
Enkephalin metabolism in anxiety 
Note: A dinucleotide polymorphism in the 5' region of 
the MME gene was linked to type of anxiety. 
T-cell apoptosis 
Note: Both, CD8+ and CD4+ T-cells express MME 
upon induction of apoptosis in vitro as well as in 
apoptotic T-cells in vivo. 
Low amplitude of the P300 evoked 
potential waves (linked to substance 
abuse) 
Note: Based on the association of MME gene 
polymorphisms with P300 wave amplitudes of the 
parietal and coronal leads, it is suggested that MME 
plays a significant role in the regulation of the 
amplitude of the P300 wave. 
It is presumed that lower molecular weight alleles of 
the MME polymorphism are associated with increased 
levels of NEP and thus lower CNS enkephalin levels. 
Recessive dystrophic epidermolysis 
bullosa 
Note: In recessive dystrophic epidermolysis bullose, 
MME activities were considerably increased in the skin 
and blister fluid samples compared with values found 
in normal control skin and in blister fluid from a patient 
with a burn. 
Acute lymphoblastic leukemia 
Note: MME is expressed in majority acute 
lymphoblastic leukemias, in which MME was 
originally described as common acute lymphocytic 
leukemia antigen (CALLA). The role of MME in acute 
leukemia is not clear. 
Burkitt lymphoma 
Note: Burkitt lymphoma/leukemia was originally 
misclassified with acute lymphoblastic leukemia due to 
its expression of CD10 and blastic cytologic 
appearance. However, now it is correctly classified as 
mature B-cell neoplasm and expression of MME 
(referred as to CD10 in this context) is secondary to its 
germinal center stage of development. In normal B-cell 
development MME transitory reappears on B-cells in 
germinal centers. 
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Follicular lymphoma and other 
malignant lymphomas 
Note: Follicular lymphomas originate from mature B- 
cells with germinal center stage of differentiation. 
Majority of follicular lymphomas typically express 
MME (referred to in this context as CD10) and its 
expression positively correlates with survival and 
negatively with the grade of follicular lymphoma. 
Other B-cell malignant lymphomas that typically 
express MME (CD10) are some diffuse large B-cell 
lymphomas (DLBCL) which are than subtyped as so-
called germinal center type (GC-type DLBCL). Of T-
cell lymphomas, angioimmunoblastic T-cell lymphoma 
typically shows expression of CD10. 
Carcinoma 
Note: MME is expressed in some carcinomas that 
originate in organs, which normally express high levels 
of MME, which is best illustrated in renal cell 
carcinoma. MME detection is important for 
identification of bile canaliculi, which appear by 
neogenesis in hepatocellular carcinoma. This feature is 
diagnostically useful in hepatocellular carcinoma. It is 
also expressed in many other carcinomas including 
prostate carcinoma, urothelial carcinoma, colorectal 
carcinoma, and others in which expression of higher 
levels of MME were associated with more aggressive 
tumors. 
Melanoma 
Note: Higher expression levels were associated with 
more aggressive disease. 
Stromal cells 
Note: Various benign stromal cells express MME. In 
particular, adipose tissue, endometrial stroma, and 
dendritic stromal cells in the bone marrow are know to 
express significant levels of MME. The role of MME in 
these tissue is not know. However, it possibly 
contributes to functional changes of the endometrial 
stromal in the secretory phase when its levels are 
highest in this tissue. It is also known that dendritic 
MME+ stromal cells of the bone marrow provide 
maturational niche for development of B-cells. Other 
MME+ benign stromal cells are induced by invasion of 
malignant tumors like melanoma, breast carcinoma, 
and others. In malignant stromal lesions MME has been 
found expressed in rhabdomyosarcoma, 
leiomyosarcoma and other sarcomas. 
Juvenile idiopathic arthritis (JIA) and 
rheumatoid arthritis (RA) 
Note: Circulating MME levels were lower in JIA 
patients than in controls, while synovial fluid values 
were higher than those found in circulation, which 
might reflect a reactive effort to control synovial 
proliferation. RA patients have higher levels of MME 
in plasma and synovial fluid than patients with 
osteoarthritis. 
Acne 
Note: Sebaceous glands in acne patients express high 
levels of MME. In addition; in vitro experiments using 
an organ culture system demonstrated that substance P 
induced expression MME in sebaceous glands in a dose 
dependent manner. 
Idiopathic diffuse hyperplasia of 
pulmonary neuroendorine cells 
(IDHPNC) 
Note: MME expression in patients with IDHPNC was 
compared with MME expression in patients with 
idiopathic pulmonary fibrosis, hypersensitivity 
pneumonitis, and normal lung by using 
immunohistochemistry, ELISA, activity assay, and 
Western blot analysis. MME expression was highest in 
IDHPNC. Increased MME expression in lung tissue 
from patients with IDHPNC may reflect a 
compensatory increase that partly counteracts abundant 
neuropeptides, including BLP, present in this disorder. 
Pathophysiology of 
ischemia/reperfusion myocardial injury 
Note: MME expression was increased in the 
neutrophils from patients with early phase of acute 
myocardial infarction (AMI) by 5.2- and by 4.2-fold of 
the neutrophils from patients with late phase of AMI, 
respectively. ANP and BNP, which increase in AMI, 
modulate the neutrophil functions and exert protective 
effects against the neutrophils-induced endothelial 
cytotoxity at the physiological concentrations. But the 
effects are suppressed due to their degradation by the 
neutrophil own MME. Thus, neutrophil MME, which 
also increases in AMI, may play a role in the 
pathophysiology of ischemia/reperfusion myocardial 
injury. 
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